MedTrace Logo

A Sickle CEll Disease ComplicatioN Trial

NCT02604368 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2019-02-01

No results posted yet for this study

Summary

The objective of this study is to assess the efficacy of SC411 in reducing the number of sickle cell crisis (SCC) events in sickle cell disease (SCD) subjects receiving SC411 compared to those subjects receiving placebo.

Conditions

Interventions

DRUG

SC411

Soft gelatin capsule

DRUG

Placebo

Soft gelatin capsule

Sponsors & Collaborators

  • Micelle BioPharma Inc

    lead INDUSTRY

Principal Investigators

  • Carton Dampier, MD · Emory University

  • Matt Heeney, MD · Harvard University

  • Beng Fuh, MD · East Carolina University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-31
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02604368 on ClinicalTrials.gov